IL13 and idiopathic pulmonary fibrosis: A phase 2 randomised, double-blind, placebo-controlled trial that assessed the safety, tolerability and change in FVC at 52 weeks of the anti–IL-13 QAX576 in 60 patients with IPF was terminated [26].